THE ELEMENT | Linksium
Back to portfolio

THE ELEMENT

Incorporated startups

Implantable device for chronic hydrogen therapy against Parkinson's disease

profilePhoto   Philippe Mattia
Linksium Contact Philippe Mattia +33 (0)4 57 13 81 65 philippe.mattia@linksium.fr
profilePhoto   Awatef Ben Tahar, CEO
THE ELEMENT Awatef Ben Tahar, CEO +33 (0)6 62 74 20 45 awatef.ben-tahar@theelement.fr
Brain2

Benefits

  • Neuroprotective treatment
  • Low invasiveness
  • Chronic treatment

Key words

  • Parkinson's disease
  • Hydrogen therapy
  • Implantable device

Intellectual Property

  • 1 patent

Partnerships & Rewards

  • Région Auvergne-Rhône-Alpes

Laboratory

  • TIMC-IMAG

Institutions

  • CNRS
  • GRENOBLE INP
  • UGA

Linksium Continuum

  • Maturation
  • Incubation

Results

  • Incorporated startups

Context

Ten million people worldwide have Parkinson's disease. This number will increase by 56% by 2030. On the one hand, the symptoms of Parkinson's disease can be treated, but on the other hand, there is no therapy to slow down the neuronal degeneration associated with the disease.

Technology

The ELEMENT develops an implantable device named HOPE "Hydrogen Operating Parkinson Elimination". HOPE is able to provide chronic hydrogen therapy. Hydrogen is a strong and selective antioxidant. It can slow down neuronal degeneration.

Advantages

  • A chronic treatment: no patient involvement for five years
  • A stable dose of hydrogen over several years
  • Minimally invasive: outpatient surgery for device implantation
  • Reduction of healthcare costs

State of progress

A first version of the HOPE device has been developed and a conclusive preclinical study on a parkinsonian rat model has been performed. The neuro-protective effect of hydrogen has been validated.

Applications

The active implantable medical device developed by the future startup THE ELEMENT targets applications in the field of neurodegenerative diseases.